Neurokinin receptor subtypes characterized by biological assays
- PMID: 8208061
- DOI: 10.1016/0024-3205(94)00712-8
Neurokinin receptor subtypes characterized by biological assays
Abstract
Neurokinin receptors have been characterized by biological assays using naturally occurring and selective agonists as well as peptide and non peptide antagonists. Six preparations have been used: the rabbit vena cava and the rat urinary bladder, treated with a NK-2 receptor antagonist for the NK-1 receptor, the rabbit pulmonary artery and the hamster urinary bladder for the NK-2, the rat portal vein and the guinea pig ileum, treated with a NK-1 receptor antagonist, for the NK-3. Treatment with antagonists was required because of the presence (in some preparations) of two functional sites contributing to the biological effect. Differences in the order of potency of agonists between each couple of receptors have been demonstrated, especially with tachykinins and the selective agonists. Such differences are even more evident with antagonists, some of which show apparent affinity (pA2) values 1.5 to 3 log units higher in one than in the other member of each couple. Based on data obtained in pharmacological experiments, it is concluded that NK-1, NK-2 and NK-3 receptors show differences strong enough to justify the assumption that their coding and/or expression diverge among species.
Similar articles
-
Functional characterization of neurokinin receptors with agonists and antagonists.Regul Pept. 1993 Jul 2;46(1-2):287-9. doi: 10.1016/0167-0115(93)90062-d. Regul Pept. 1993. PMID: 7692518 No abstract available.
-
Pharmacological characterization of SR 142801: a new non-peptide antagonist of the neurokinin NK-3 receptor.Pharmacology. 1996 May;52(5):283-91. doi: 10.1159/000139393. Pharmacology. 1996. PMID: 8807672
-
Two NK-3 receptor subtypes: demonstration by biological and binding assays.Neuropeptides. 1994 Sep;27(3):157-61. doi: 10.1016/0143-4179(94)90065-5. Neuropeptides. 1994. PMID: 7529376
-
Bradykinin receptor types and B2 subtypes.Life Sci. 1994;55(10):735-49. doi: 10.1016/0024-3205(94)00557-5. Life Sci. 1994. PMID: 8072371 Review.
-
Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases.Expert Opin Ther Targets. 2003 Jun;7(3):343-62. doi: 10.1517/14728222.7.3.343. Expert Opin Ther Targets. 2003. PMID: 12783571 Review.
Cited by
-
Modulation of cardiac activity by tachykinins in the rat substantia nigra.Br J Pharmacol. 2001 Dec;134(8):1749-59. doi: 10.1038/sj.bjp.0704401. Br J Pharmacol. 2001. PMID: 11739252 Free PMC article.
-
Implication of nigral tachykinin NK3 receptors in the maintenance of hypertension in spontaneously hypertensive rats: a pharmacologic and autoradiographic study.Br J Pharmacol. 2003 Feb;138(4):554-63. doi: 10.1038/sj.bjp.0705042. Br J Pharmacol. 2003. PMID: 12598409 Free PMC article.
-
Tachykinins and tachykinin receptors in human uterus.Br J Pharmacol. 2003 Jun;139(3):523-32. doi: 10.1038/sj.bjp.0705279. Br J Pharmacol. 2003. PMID: 12788812 Free PMC article.
-
Autocrine proliferation of neuroblastoma cells is partly mediated through neurokinin receptors: relevance to bone marrow metastasis.J Neurooncol. 2005 Jan;71(2):91-8. doi: 10.1007/s11060-004-9182-2. J Neurooncol. 2005. PMID: 15690122
-
The predicting role of substance P in the neoplastic transformation of the hypoplastic bone marrow.J Clin Pathol. 2006 Sep;59(9):935-41. doi: 10.1136/jcp.2005.034629. J Clin Pathol. 2006. PMID: 16935970 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources